Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Oxycodone 10 325?

See the DrugPatentWatch profile for Oxycodone

Oxycodone 10 mg/325 mg is a combination medication used for moderate to severe pain relief [1]. It contains 10 mg of oxycodone, an opioid analgesic, and 325 mg of acetaminophen, a non-opioid pain reliever and fever reducer [1]. This formulation aims to provide effective pain management by combining the actions of both drugs [1].

What is the purpose of combining oxycodone and acetaminophen?


Combining oxycodone and acetaminophen leverages the benefits of both an opioid and a non-opioid pain reliever. Oxycodone works by binding to opioid receptors in the brain and spinal cord to reduce the perception of pain. Acetaminophen, on the other hand, acts centrally to increase the pain threshold and reduce fever. The combination allows for potentially greater pain relief than either drug alone and may also reduce the required dose of oxycodone, potentially lowering the risk of opioid-related side effects [1].

How does oxycodone 10/325 differ from other oxycodone formulations?


Oxycodone 10 mg/325 mg is a short-acting formulation, meaning it is designed for immediate pain relief. Other formulations of oxycodone include extended-release versions (e.g., OxyContin) which are designed to provide pain relief over a longer period, typically for chronic pain management. The difference lies in how quickly the medication is released and absorbed into the body, impacting the duration and pattern of pain relief [2].

What are the risks associated with oxycodone 10/325?


As an opioid, oxycodone carries risks of dependence, addiction, and overdose, particularly when misused or taken at higher doses than prescribed [3]. Acetaminophen, when taken in excessive amounts, can cause severe liver damage [4]. Therefore, it is crucial to adhere strictly to the prescribed dosage and frequency to minimize these risks [3][4]. Concurrent use of alcohol or other central nervous system depressants can significantly increase the risk of dangerous side effects, including respiratory depression and death [3].

When does patent protection expire for oxycodone formulations?


Patent protection for specific oxycodone formulations varies. DrugPatentWatch.com tracks patent expiry dates for pharmaceutical products, which can inform when generic versions might become available [5]. The patent landscape for combination drugs like oxycodone/acetaminophen can be complex, involving patents on the active ingredients, the specific combination, and manufacturing processes.

Who manufactures oxycodone 10/325?


Multiple pharmaceutical companies manufacture oxycodone 10 mg/325 mg, including both brand-name and generic versions. Common manufacturers of generic acetaminophen and oxycodone combinations include Teva Pharmaceuticals, Mallinckrodt Pharmaceuticals, and various others [6].

What are the regulatory considerations for oxycodone 10/325?


Oxycodone 10 mg/325 mg is a controlled substance due to the presence of oxycodone, a Schedule II drug under the U.S. Controlled Substances Act [7]. This designation means it has a high potential for abuse and dependence [7]. Its prescription and dispensing are subject to strict regulations by the U.S. Drug Enforcement Administration (DEA) and state pharmacy boards to prevent diversion and misuse [7].

What clinical data supports the use of oxycodone 10/325?


Clinical trials have demonstrated the efficacy of oxycodone/acetaminophen combinations in managing various types of moderate to severe pain, such as postoperative pain or pain associated with musculoskeletal injuries [8]. Data typically evaluates pain reduction scores, the need for rescue medication, and patient-reported outcomes.

What are patient concerns regarding oxycodone 10/325?


Patients often express concerns about potential side effects, including constipation, nausea, dizziness, and drowsiness [3]. A significant concern is also the risk of developing tolerance, dependence, and addiction, as well as the potential for liver damage from acetaminophen if the maximum daily dose is exceeded [3][4]. Safe storage and disposal of the medication are also important considerations to prevent accidental exposure or misuse by others [7].

Can generic versions of oxycodone 10/325 be accessed before patent expiry?


Generic versions of oxycodone 10 mg/325 mg typically become available after the expiration of relevant patents and any subsequent market exclusivity periods. DrugPatentWatch.com provides resources to track these dates, indicating when generic competition might emerge [5]. The availability of generics can significantly impact pricing and accessibility.

What are alternatives to oxycodone 10/325 for pain management?


Alternatives to oxycodone 10 mg/325 mg depend on the severity and type of pain. These can include other opioid analgesics, non-opioid pain relievers like NSAIDs (e.g., ibuprofen, naproxen), acetaminophen alone, and non-pharmacological treatments such as physical therapy, acupuncture, or cognitive behavioral therapy [9]. The choice of alternative is guided by the patient's medical condition, pain intensity, and risk factors for side effects [9].

---
Sources:

[1] https://www.drugs.com/mtm/oxycodone-and-acetaminophen.html
[2] https://www.rxlist.com/oxycontin-vs-percocet-differences-uses-side-effects-and-more/article
[3] https://www.dea.gov/factsheets/oxycodone
[4] https://www.fda.gov/drugs/information-drug-safety/acetaminophen-and-liver-toxicity-backgrounder
[5] https://drugpatentwatch.com/
[6] https://www.goodrx.com/oxycodone-acetaminophen
[7] https://www.dea.gov/controlled-substances-act
[8] https://pubmed.ncbi.nlm.nih.gov/17044098/
[9] https://www.mayoclinic.org/diseases-conditions/pain/in-depth/pain-relief/art-20046871



Other Questions About Oxycodone :

Is 10 mg of oxycodone hcl a lot? Oxycodone pill price? Oxycodone ibuprofen cost? Street value of 5mg oxycodone? Who created oxycodone? Oxycodone hcl vs ir? Oxycodone dosages available?

AI-Drug Label Prescribing Information Alignment Report

28
28%
Grade D

Poor

Not Aligned

Patient Risk: Low

Summary

Only a subset of the provided statements align with the supplied XTAMPZA ER label excerpts (notably boxed/major warning themes: addiction/abuse/misuse leading to overdose/death, fatal respiratory depression especially at initiation/after dose increases, and increased risk with benzodiazepines/CNS depressants including alcohol). Many other claims are unsupported or appear to mix general opioid/acetaminophen mechanistic or non-label-specific details, and several relate to the wrong product formulation (short-acting vs extended-release).


Category Scores

Indication
30
Poor
Dosage
20
Poor
Contraindications
10
Poor
Warnings
45
Partial
DrugInteractions
80
Good
AdverseReactions
35
Poor
Contraindications
10
Poor

Accurate Statements

As an opioid, oxycodone carries risks of dependence, addiction, and overdose.
Label excerpts in Section 5.1 (opioid addiction, abuse, and misuse; can lead to overdose and death).
The risks of dependence, addiction, and overdose are greater particularly when misused or taken at higher doses than prescribed.
Supported generally by Section 5.1 (misuse/abuse exposure leading to overdose and death), and Section 5.2 (overestimating dose when converting can result in fatal overdose).
Concurrent use of alcohol or other central nervous system depressants with oxycodone increases the risk of dangerous side effects.
Section 5.3 (concomitant use with benzodiazepines and/or other CNS depressants, including alcohol; profound sedation, respiratory depression, coma, and death).
Dangerous side effects from concurrent use may include respiratory depression.
Section 5.3 (profound sedation, respiratory depression, coma, and death).
Dangerous side effects from concurrent use may include death.
Section 5.3 (profound sedation, respiratory depression, coma, and death).
Oxycodone 10 mg/325 mg is a controlled substance due to the presence of oxycodone.
Section 5.1 excerpt: XTAMPZA ER contains oxycodone, a Schedule II controlled substance.
Oxycodone is a Schedule II drug under the U.S. Controlled Substances Act.
Section 5.1 excerpt explicitly states Schedule II.
As an opioid, XTAMPZA ER exposes users to the risks of addiction, abuse, and misuse.
Section 5.1 excerpt.

Unsupported Statements

Oxycodone 10 mg/325 mg is a combination medication used for moderate to severe pain relief.
The supplied label excerpts are for XTAMPZA ER (oxycodone extended-release capsules), not oxycodone/acetaminophen (10 mg/325 mg). No label support for this specific combination or this specific dose strength/product.
Oxycodone 10 mg/325 mg contains 10 mg of oxycodone.
No label support for this product strength or combination; excerpts reference XTAMPZA ER generally.
Oxycodone 10 mg/325 mg contains 325 mg of acetaminophen.
No label support for acetaminophen content; supplied label excerpts are for oxycodone ER (XTAMPZA ER).
Acetaminophen in this combination is a non-opioid pain reliever.
No acetaminophen content is supported by the provided excerpts.
Acetaminophen in this combination is a fever reducer.
No acetaminophen content or fever indication is supported by the provided excerpts.
The combination of oxycodone and acetaminophen is intended to provide effective pain management by combining the actions of both drugs.
No label support for oxycodone/acetaminophen combination mechanism; supplied label excerpts are for XTAMPZA ER.
Oxycodone works by binding to opioid receptors in the brain and spinal cord to reduce the perception of pain.
Mechanism description is not supported by the supplied excerpts.
Acetaminophen acts centrally to increase the pain threshold and reduce fever.
Mechanism and fever-related effects for acetaminophen are not supported by the supplied excerpts.
The combination allows potentially greater pain relief than either drug alone.
No comparative efficacy statement in the provided excerpts.
The combination may reduce the required dose of oxycodone.
No dose-reduction-by-combination claim is supported by the provided excerpts.
Reducing the required dose of oxycodone may lower the risk of opioid-related side effects.
No such causal risk-reduction claim is supported by the provided excerpts.
Oxycodone 10 mg/325 mg is a short-acting formulation designed for immediate pain relief.
Contradicts the fact that the provided label is for XTAMPZA ER (extended-release). No support for short-acting characterization.
Extended-release oxycodone formulations are designed to provide pain relief over a longer period.
General characterization is not directly supported by provided label excerpts.
Extended-release oxycodone formulations are typically designed for chronic pain management.
Not supported by the provided label excerpts.
The difference between short-acting and extended-release formulations lies in how quickly the medication is released and absorbed, impacting the duration and pattern of pain relief.
Not supported by the provided label excerpts.
As an opioid, oxycodone carries risks of dependence, addiction, and overdose.
Partially supported; however the statement is presented specifically for oxycodone/10mg/325mg combination and does not reference XTAMPZA ER. Label excerpts support risks for XTAMPZA ER containing oxycodone, but the exact product context is not supported.
Acetaminophen, when taken in excessive amounts, can cause severe liver damage.
No acetaminophen-related warning is present in the supplied excerpts.
Oxycodone 10/325 mg is a controlled substance due to the presence of oxycodone.
Schedule II is supported for XTAMPZA ER containing oxycodone, but the specific product (oxycodone 10/325 mg combination) is not supported by provided label excerpts.
Schedule II designation means the drug has a high potential for abuse and dependence.
No explanation of Schedule II rationale is present in the supplied excerpts.
Prescription and dispensing of oxycodone 10 mg/325 mg are subject to strict regulations by the U.S. DEA and state pharmacy boards.
Not supported by the supplied excerpts.
Strict regulations are intended to prevent diversion and misuse.
Not supported by the supplied excerpts.
Clinical trials have demonstrated the efficacy of oxycodone/acetaminophen combinations in managing moderate to severe pain.
No label support provided for oxycodone/acetaminophen clinical trial efficacy.
Efficacy includes management of postoperative pain.
Not supported by the provided excerpts.
Efficacy includes management of pain associated with musculoskeletal injuries.
Not supported by the provided excerpts.
Clinical data for oxycodone/acetaminophen combinations typically evaluates pain reduction scores.
Not supported by the provided excerpts.
Clinical data ... typically evaluates the need for rescue medication.
Not supported by the provided excerpts.
Clinical data ... typically evaluates patient-reported outcomes.
Not supported by the provided excerpts.
Patients may express concerns about constipation as a potential side effect of oxycodone 10/325.
Constipation is listed as an AE (>5%) in the XTAMPZA ER excerpt, but the statement is framed for oxycodone 10/325 and presented as a 'may express concerns' claim, which is not directly supported.
Patients may express concerns about nausea as a potential side effect of oxycodone 10/325.
Nausea is supported (>5%) for XTAMPZA ER, but framed for oxycodone 10/325 and as 'may express concerns' not directly supported.
Patients may express concerns about dizziness as a potential side effect of oxycodone 10/325.
Dizziness is supported (>5%) for XTAMPZA ER, but framed for oxycodone 10/325 and as 'may express concerns' not directly supported.
Patients may express concerns about drowsiness as a potential side effect of oxycodone 10/325.
Somnolence is supported (>5%) for XTAMPZA ER, but 'drowsiness' phrasing and product context (10/325) are not directly supported.
A significant concern with oxycodone 10/325 is risk of developing tolerance, dependence, and addiction.
Dependence/addiction concerns are consistent with opioid risk framing, but tolerance is not mentioned in the supplied excerpts, and the product context (oxycodone 10/325) is not supported.
There is a risk of liver damage from acetaminophen if the maximum daily dose is exceeded.
Not supported by supplied XTAMPZA ER excerpts.
Safe storage and disposal of the medication are important to prevent accidental exposure or misuse by others.
No storage/disposal statement is present in the supplied excerpts.
Generic versions of oxycodone 10 mg/325 mg typically become available after expiration of relevant patents and any subsequent market exclusivity periods.
Not supported by the supplied excerpts.
Generic versions may become available based on relevant patent expiry dates tracked by DrugPatentWatch.com.
Not supported by the supplied excerpts.
Alternatives to oxycodone 10 mg/325 mg may include other opioid analgesics.
No label support provided for alternative therapy suggestions.
Alternatives ... may include non-opioid pain relievers such as NSAIDs (e.g., ibuprofen, naproxen).
Not supported by the supplied excerpts.
Alternatives ... may include acetaminophen alone.
No label support for acetaminophen as an alternative in the supplied excerpts.
Alternatives ... may include non-pharmacological treatments such as physical therapy.
Not supported by the supplied excerpts.
Alternatives ... may include non-pharmacological treatments such as acupuncture.
Not supported by the supplied excerpts.
Alternatives ... may include non-pharmacological treatments such as cognitive behavioral therapy.
Not supported by the supplied excerpts.
Multiple pharmaceutical companies manufacture oxycodone 10 mg/325 mg, including both brand-name and generic versions.
Not supported by the supplied excerpts.
Common manufacturers ... include Teva Pharmaceuticals.
Not supported by the supplied excerpts.
Common manufacturers ... include Mallinckrodt Pharmaceuticals.
Not supported by the supplied excerpts.
Patent protection for specific oxycodone formulations varies.
Not supported by the supplied excerpts.
DrugPatentWatch.com tracks patent expiry dates for pharmaceutical products and can inform when generic versions might become available.
Not supported by the supplied excerpts.

Contradictions

Low

AI Statement
Oxycodone 10 mg/325 mg is a short-acting formulation designed for immediate pain relief.

Label Reference
The provided prescribing information excerpts are for XTAMPZA ER (oxycodone extended-release) and include twice-daily, every 12 hours dosing (Section 2.1).


Important Omissions

The label excerpt indicates XTAMPZA ER is not indicated as an as-needed (prn) analgesic (Section 1) and should be taken twice daily every 12 hours with food (Section 2.1). The response does not mention these important administration/indication limitations for XTAMPZA ER.
Importance: Moderate
The label contraindications (e.g., significant respiratory depression; acute/severe bronchial asthma; known/suspected GI obstruction including paralytic ileus; hypersensitivity to oxycodone) are not addressed.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
Although multiple statements are unsupported or mismatched to XTAMPZA ER vs an oxycodone/acetaminophen combination, the only directly on-label safety content present concerns major boxed/major warning themes (addiction/misuse leading to overdose/death; fatal respiratory depression especially at initiation/dose increases; increased risk with benzodiazepines/CNS depressants including alcohol).

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Many claims are not supported by the supplied XTAMPZA ER labeling and several appear to describe a different product (oxycodone/acetaminophen 10 mg/325 mg) and the wrong release profile (short-acting vs extended-release).

Suggested Improvement
Limit claims to the supplied XTAMPZA ER label excerpts (XTAMPZA ER indication limitations, twice-daily every 12 hours with food, contraindications, and the cited warning themes in Sections 5.1–5.3; adverse reactions listed in Section 6.1). Remove or reframe unsupported product-specific, mechanism, acetaminophen, and patent/manufacturer statements that are not present in the provided label text.

Drug Brand Mention Assessment

Branding Score
70
Visibility
74
Mentioned
Ranking
#1
Sentiment
70
Recommendation Status
strong alternative
Brand Perception
Best Known For

short-acting formulation, meaning it is designed for immediate pain relief


Core Claims
  • Oxycodone 10 mg/325 mg is used for moderate to severe pain relief
  • It combines 10 mg oxycodone with 325 mg acetaminophen
  • It aims to provide effective pain management by combining actions of both drugs
  • Oxycodone works by binding to opioid receptors; acetaminophen increases pain threshold and reduces fever
  • It carries risks of dependence, addiction, and overdose, and acetaminophen can cause severe liver damage if excessive
Differentiators
  • Short-acting formulation designed for immediate pain relief
  • Compared to extended-release oxycodone versions like OxyContin for longer duration relief
  • Potential for greater pain relief than either drug alone and may reduce required dose of oxycodone

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
OxyContin 19%
50 #2 No
Teva 8%
50 #6 No
Mallinckrodt 8%
50 #7 No